[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338164-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338164-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","reduction-of-false-positives-using-zone-specific-prostate-specific-antigen-density-for-prostate-mri-based-biopsy-decision-strategies","Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies","","Zone-specific prostate-specific antigen density (sPSAD) is evaluated to improve prostate MRI-based biopsy decision strategies for detecting Grade Group ≥ 2 prostate cancer while reducing false-positive biopsies. A retrospective cohort of consecutive patients undergoing MRI and biopsy from 01/2012 to 10/2018 used deep learning (nnU-Net) to segment the whole gland and transition zone and compute PSAD and sPSAD. sPSAD combined with PI-RADS increases specificity and lowers false positives with maintained sensitivity, guiding biopsies in PI-RADS 3 lesions when sPSAD meets a threshold.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/reduction-of-false-positives-using-zone-specific-prostate-specific-antigen-density-for-prostate-mri-based-biopsy-decision-strategies/338164/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/reduction-of-false-positives-using-zone-specific-prostate-specific-antigen-density-for-prostate-mri-based-biopsy-decision-strategies/338164.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of using sPSAD in prostate MRI-based biopsy decisions?","Question",{"text":63,"@type":64},"To develop and test zone-specific prostate-specific antigen density combined with PI-RADS to guide biopsy decision strategies that reduce false positives while maintaining high sensitivity for Grade Group ≥ 2 cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were sPSAD and PI-RADS combined in the biopsy decision strategies?",{"text":68,"@type":64},"The whole gland and transition zone were segmented on MRI using a retrained deep learning system (nnU-Net) to calculate PSAD and sPSAD. Then, sPSAD and PI-RADS were combined in a decision strategy, with biopsy selection based on PI-RADS categories and an sPSAD threshold for PI-RADS 3 lesions.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key performance outcomes regarding false positives and specificity?",{"text":72,"@type":64},"When using the sPSAD-based strategy, false positives were reduced by 25%. Specificity doubled from 18% to 43% when biopsies were taken in PI-RADS 4–5 and in PI-RADS 3 only if sPSAD was above 0.42 ng/mL/cc, with similar sensitivity maintained.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338164,1790319223,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Hamm et al. European Radiology (2024) 34:6229-6240  \n[https://doi.org/10.1007/s00330-024-10700-z](https://doi.org/10.1007/s00330-024-10700-z)  \nUROGENITAL  \nReduction of false positives using  \nzone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies  \nCharlie A. Hamm 1,2*, Georg L. Baumgärtner 1 , Anwar R. Padhani3, Konrad P. Froböse 1, Franziska Dräger 1, Nick L. Beetz 1,2, Lynn J. Savic 1,2 , Helena Posch1, Julian Lenk1, Simon Schallenberg4, Andreas Maxeiner5, Hannes Cash6, Karsten Günzel7, Bernd Hamm 1, Patrick Asbach1 and Tobias Penzkofer 1,2  \nAbstract  \nObjectives To develop and test zone-specific prostate-specific antigen density (sPSAD) combined with PI-RADSto guide prostate biopsy decision strategies (BDS) .  \nMethods This retrospective study included consecutive patients, who underwent prostate MRI and biopsy (01/2012– 10/2018) . The whole gland and transition zone (TZ) were segmented at MRI using a retrained deep learning system (DLS; nnU-Net) to calculate PSAD and sPSAD, respectively. Additionally, sPSAD and PI-RADS were combined in a BDS, and diagnostic performances to detect Grade Group ≥ 2 (GG ≥ 2) prostate cancer were compared. Patient-based cancer detection using sPSAD was assessed by bootstrapping with 1000 repetitions and reported as area under the curve (AUC) . Clinical utility of the BDS was tested in the hold-out test set using decision curve analysis. Statistics included nonparametric DeLong test for AUCs and Fisher-Yates test for remaining performance metrics.  \nResults A total of 1604 patients aged 67 (interquartile range, 61–73) with 48% GG ≥ 2 prevalence (774/1604) were evaluated. By employing DLS-based prostate and TZ volumes (DICE coefficients of 0.89 (95% confidence interval, 0.80–0. 97) and 0.84 (0 .70–0. 99)), GG ≥ 2 detection using PSAD was inferior to sPSAD (AUC, 0.71 (0 .68–0. 74)/0 .73 (0 .70–0. 76); p \u003C 0 . 001) . Combining PI-RADS with sPSAD, GG ≥ 2 detection specificity doubled from 18%(10–20%) to 43%(30–44%; p \u003C 0 . 001) with similar sensitivity (93%(89–96%)/97%(94–99%); p = 0 . 052), when biopsies were taken in PI-RADS 4-5 and 3 only if sPSAD was ≥ 0.42 ng/mL/cc as compared to all PI-RADS 3-5 cases. Additionally, using the sPSAD-based BDS, false positives were reduced by 25%(123 (104–142)/165 (146–185); p \u003C 0. 001) . Conclusion Using sPSAD to guide biopsy decisions in PI-RADS 3 lesions can reduce false positives at MRI while maintaining high sensitivity for GG ≥ 2 cancers.  \nClinical relevance statement Transition zone-specific prostate-specific antigen density can improve the accuracy of prostate cancer detection compared to MRI assessments alone, by lowering false-positive cases without significantly missing men with ISUP GG ≥ 2 cancers.  \n*Correspondence:  \nCharlie A. Hamm  \n[Charlie.hamm@charite.de](Charlie.hamm@charite.de)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024, corrected publication 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \n6230 Hamm etal. European Radiology (2024) 34:6229-6240  \nKey Poin","cbCaigztnzcc0khl","https://ap.wps.com/l/cbCaigztnzcc0khl","pdf",3550217,12,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusion\n## Clinical relevance statement\n# Key Points\n# Introduction","[{\"question\":\"What is the main goal of using sPSAD in prostate MRI-based biopsy decisions?\",\"answer\":\"To develop and test zone-specific prostate-specific antigen density combined with PI-RADS to guide biopsy decision strategies that reduce false positives while maintaining high sensitivity for Grade Group ≥ 2 cancers.\"},{\"question\":\"How were sPSAD and PI-RADS combined in the biopsy decision strategies?\",\"answer\":\"The whole gland and transition zone were segmented on MRI using a retrained deep learning system (nnU-Net) to calculate PSAD and sPSAD. Then, sPSAD and PI-RADS were combined in a decision strategy, with biopsy selection based on PI-RADS categories and an sPSAD threshold for PI-RADS 3 lesions.\"},{\"question\":\"What were the key performance outcomes regarding false positives and specificity?\",\"answer\":\"When using the sPSAD-based strategy, false positives were reduced by 25%. Specificity doubled from 18% to 43% when biopsies were taken in PI-RADS 4–5 and in PI-RADS 3 only if sPSAD was above 0.42 ng/mL/cc, with similar sensitivity maintained.\"}]","Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies | PDF",1790022310,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a561a26197a8a757097729b477045661.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/354870d4939a3a6ab7bec32145acd018.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88c8f3bfd8d6214eaf9ffb5bad0ce3ea.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ab4061775fc52097a47242b6ba56ddc.webp",980,1301]